1
|
Zeine F, Jafari N, Baron D, Bowirrat A, Pinhasov A, Norling B, Martinez KC, Nami M, Manavi N, Sunder K, Rabin DM, Bagchi D, Khalsa J, Gold MS, Sipple D, Barzegar M, Bodhanapati J, Khader W, Carney P, Dennen CA, Gupta A, Elman I, Badgaiyan RD, Modestino EJ, Thanos PK, Hanna C, McLaughlin T, Cadet JL, Soni D, Braverman ER, Barh D, Giordano J, Edwards D, Ashford JW, Gondre-Lewis MC, Gilley E, Murphy KT, Lewandrowski KU, Sharafshah A, Makale M, Fuehrlein B, Blum K. Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy. JOURNAL OF ADDICTION PSYCHIATRY 2024; 8:50-95. [PMID: 39635461 PMCID: PMC11615735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/07/2024]
Abstract
Objectives The opioid crisis in the last few decades has mounted to a global level, impacting all areas of socioeconomic, demographic, geographic, and cultural boundaries. Traditional treatments have not been deemed to show the degree of efficacy necessary to address the crisis. The authors of this review paper have set forth an unprecedented and in-depth look into multi-factorial determinants that have contributed to the opioid crisis becoming global and multi-faceted. Methods For this narrative review/opinion article, we searched PsychINFO, PubMed, Google Scholar, and Web of Science databases to identify relevant articles on topics including the "opioid crisis," "opioid mechanisms," "genetics and epigenetics," "neuropharmacology," and "clinical aspects of opioid treatment and prevention." Since this was not a systematic review the articles selected could represent unitential bias. Results Despite some success achieved through Opioid Substitution Therapy (OST) in harm reduction, the annual mortality toll in the US alone surpasses 106,699 individuals, a figure expected to climb to 165,000 by 2025. Data from the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Survey on Drug Abuse and Health (NSDUH) reveals that approximately 21.4% of individuals in the US engaged in illicit drug use in 2020, with 40.3 million individuals aged 12 or older experiencing a Substance Use Disorder (SUD). Provisional figures from the Centers for Disease Control and Prevention (CDC) indicate a troubling 15% increase in overdose deaths in 2021, rising from 93,655 in 2020 to 107,622, with opioids accounting for roughly 80,816 of these deaths. Conclusions We advocate reevaluating the "standard of care" and shifting towards inducing dopamine homeostasis by manipulating key neurotransmitter systems within the brain's reward cascade. We propose a paradigm shift towards a novel "standard of care" that begins with incorporating Genetic Addiction Risk Severity (GARS) testing to assess pre-addiction risk and vulnerability to opioid-induced addiction; emphasis should be placed on inducing dopamine homeostasis through safe and non-addictive alternatives like KB220, and comprehensive treatment approaches that address psychological, spiritual, and societal aspects of addiction through Awareness Integration Therapy (AIT).
Collapse
Affiliation(s)
- Foojan Zeine
- Awareness Integration Institute, San Clemente, USA
- Department of Health Science, California State University, Long Beach, USA
| | - Nicole Jafari
- Department of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, USA
- Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, USA
| | - David Baron
- Center for Exercise and Sport Mental Health, Western University Health Sciences, Pomona, USA
| | - Abdalla Bowirrat
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
| | - Albert Pinhasov
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
| | - Brian Norling
- MEMS Precision Technology, Inc., Santa Barbara, USA
- Acies Biomedical, Inc. Santa Barbara, USA
| | - Kathleen Carter Martinez
- Division of General Education-Berkeley College, Paramus Campus, New Jersey, USA
- Chey-Wind Center for Trauma and Healing, Peru, USA
| | - Mohammad Nami
- Brain, Cognition, and Behavior Unit, Brain Hub Academy, Dubai, UAE
| | - Nima Manavi
- College of Osteopathic Medicine, Western University of Health Sciences, Pomona, USA
| | - Keerthy Sunder
- Department of Psychiatry, University of California, UC Riverside School of Medicine, Riverside, USA
- Division of Neuromodulation Research, Karma Doctors and Karma TMS, Palm Springs, USA
| | | | - Debasis Bagchi
- Division of Nutrigenomics, Victory Nutrition International, LLC, Bonita Springs, USA
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, USA
| | - Jag Khalsa
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Mark S. Gold
- Department of Psychiatry, Washington University, School of Medicine, St. Louis, USA
| | - Daniel Sipple
- Minnesota Institute for Pain Management, Minnesota, USA
| | - Mojtaba Barzegar
- Hamad Medical Corporation, National Center for Cancer Care and Research (NCCCR), Doha, Qatar
| | - Jothsna Bodhanapati
- Division of Neuromodulation Research, Karma Doctors and Karma TMS, Palm Springs, USA
| | - Waseem Khader
- Karma Doctors, Palm Springs, USA
- Global Medical Detox Center, Menifee, CA, USA
| | - Paul Carney
- Division of Pediatric Neurology, University of Missouri, School of Medicine, Columbia, USA
| | - Catherine A. Dennen
- Department of Family Medicine, Jefferson Health Northeast, Philadelphia, USA
| | | | - Igor Elman
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
- Department of Psychiatry, Harvard School of Medicine, Cambridge, USA
| | - Rajendra D. Badgaiyan
- Department of Psychiatry, Case Western University School of Medicine, The Metro Health System, Cleveland, USA
- Department of Psychiatry, Mt. Sinai University, Ichan School of Medicine, New York, USA
| | | | - Panayotis K. Thanos
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, USA
| | - Colin Hanna
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University at Buffalo, Buffalo, USA
| | - Thomas McLaughlin
- Division of Primary Care Research, Reward Deficiency Syndrome Clinics of America, Inc. Austin, USA
| | - Jean Lud Cadet
- Molecular Neuropsychiatry Research Branch, NIH National Institute on Drug Abuse, Baltimore, USA
| | - Diwanshu Soni
- College of Osteopathic Medicine, Western University of Health Sciences, Pomona, USA
| | - Eric R. Braverman
- Division of Clinical Neurological Research, The Kenneth Blum Neurogenetic and Behavioral Institute, LLC., Austin, USA
| | - Debmalya Barh
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
| | | | | | - J. Wesson Ashford
- Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, USA
| | | | | | - Kevin T. Murphy
- Department of Radiation Oncology, University of California, San Diego, La Jolla, USA
| | - Kai-Uwe Lewandrowski
- Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, USA
- Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia
- Department of Orthopedics, Hospital Universitário Gaffrée Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Alireza Sharafshah
- Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Milan Makale
- Department of Radiation Oncology, University of California, San Diego, La Jolla, USA
| | - Brian Fuehrlein
- Department of Psychiatry, School of Medicine, Yale University, New Haven, USA
| | - Kenneth Blum
- Center for Exercise and Sport Mental Health, Western University Health Sciences, Pomona, USA
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
- Division of Primary Care Research, Reward Deficiency Syndrome Clinics of America, Inc. Austin, USA
- Division of Clinical Neurological Research, The Kenneth Blum Neurogenetic and Behavioral Institute, LLC., Austin, USA
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
- JC’s Recovery and Counseling Center, Hollywood, USA
- Department of Psychiatry, University of Vermont, Burlington, USA
- Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, USA
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
- Center for Advanced Spine Care of Southern Arizona, Tucson, USA
| |
Collapse
|
2
|
Newberg AB, Wintering NA, Hriso C, Vedaei F, Gottfried S, Ross R. Neuroimaging evaluation of the long term impact of a novel paired meditation practice on brain function. FRONTIERS IN NEUROIMAGING 2024; 3:1368537. [PMID: 38915737 PMCID: PMC11194388 DOI: 10.3389/fnimg.2024.1368537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 05/23/2024] [Indexed: 06/26/2024]
Abstract
Background A growing number of advanced neuroimaging studies have compared brain structure and function in long term meditators to non-meditators. The goal is to determine if there may be long term effects on the brain from practicing meditation. In this paper, we present new data on the long term effects of a novel meditation practice in which the focus is on clitoral stimulation. The findings from such a study have implications for potential therapeutic uses with regard to various neurological or psychiatric conditions. Methods We evaluated the cerebral glucose metabolism in 40 subjects with an extended history (>1 year of practice, 2-3 times per week) performing the meditation practice called Orgasmic Meditation (OM) and compared their brains to a group of non-meditating healthy controls (N = 19). Both meditation and non-meditation subjects underwent brain PET after injection with 148 to 296 MBq of FDG using a standard imaging protocol. Resting FDG PET scans of the OM group were compared to the resting scans of healthy, non-meditating, controls using statistical parametric mapping. Results The OM group showed significant differences in metabolic activity at rest compared to the controls. Specifically, there was significantly lower metabolism in select areas of the frontal, temporal, and parietal lobes, as well as the anterior cingulate, insula, and thalamus, in the OM group compared to the controls. In addition, there were notable distinctions between the males and females with the females demonstrating significantly lower metabolism in the thalamus and insula. Conclusions Overall, these findings suggest that the long term meditation practitioners of OM have different patterns of resting brain metabolism. Since these areas of the brain in which OM practitioners differ from controls are involved in cognition, attention, and emotional regulation, such findings have implications for understanding how this meditation practice might affect practitioners over long periods of time.
Collapse
Affiliation(s)
- Andrew B. Newberg
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, United States
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Nancy A. Wintering
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, United States
| | - Chloe Hriso
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, United States
| | - Faezeh Vedaei
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Sara Gottfried
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, United States
| | - Reneita Ross
- Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, PA, United States
| |
Collapse
|
3
|
Newberg AB, Wintering NA, Hriso C, Vedaei F, Mohamed FB, Gottfried SE, Ross R. Alterations in cerebral glucose metabolism measured by FDG PET in subjects performing a meditation practice based on clitoral stimulation. F1000Res 2023; 11:1015. [PMID: 39931656 PMCID: PMC11809681 DOI: 10.12688/f1000research.122351.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/07/2025] [Indexed: 02/13/2025] Open
Abstract
Background The relationship between sexuality, or the libido, and spirituality or religion has long been debated in psychiatry. Recent studies have explored the neurophysiology of both sexual experiences and spiritual practices such as meditation or prayer. In the present study, we report changes in cerebral glucose metabolism in a unique meditation practice augmented by clitoral stimulation called, Orgasmic Meditation, in which a spiritual state is described to be attained by both male and female participants engaged in the practice as a pair. Methods Male (N=20) and female (N=20) subjects had an intravenous catheter connected to a bag of normal saline inserted prior to the practice. During the practice, men stimulated their partner's clitoris for exactly 15 minutes (he received no sexual stimulation). Midway through the practice, researchers injected 18F-fluorodeoxyglucose so the scan would reflect cerebral metabolism during the practice. Positron emission tomography (PET) imaging was performed approximately 30 minutes later. Results In the female participants, the meditation state showed significant decreases in the left inferior frontal, inferior parietal, insula, middle temporal, and orbitofrontal regions as well as in the right angular gyrus, anterior cingulate and parahippocampus compared to a neutral state (p<0.01). Male subjects had significant decreases in the left middle frontal, paracentral, precentral, and postcentral regions as well as the right middle frontal and paracentral regions during meditation (p<0.01). Men also had significantly increased metabolism in the cerebellum and right postcentral and superior temporal regions (p<0.01). Conclusions These findings represent a distinct pattern of brain activity, for both men and women, that is a hybrid between that of other meditation practices and sexual stimulation. Such findings have potential psychotherapeutic implications and may deepen our understanding of the relationship between spiritual and sexual experience.
Collapse
Affiliation(s)
- Andrew B. Newberg
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Nancy A. Wintering
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Chloe Hriso
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Faezeh Vedaei
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Feroze B. Mohamed
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Sara E. Gottfried
- Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| | - Reneita Ross
- Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, PA, 19107, USA
| |
Collapse
|